Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 12 publications
A novel orf virus vector-based COVID-19 booster vaccine shows cross-neutralizing activity in the absence of anti-vector neutralizing immunity.
Journal: Human vaccines & immunotherapeutics
Published: October 14, 2024
Immunogenicity, efficacy, and safety of biosimilar insulin glargine (Gan & Lee glargine) compared with originator insulin glargine (Lantus®) in patients with type 2 diabetes after 26 weeks' treatment: A randomized open label study.
Journal: Diabetes, obesity & metabolism
Published: December 13, 2023
Cardiometabolic risk factors efficacy of semaglutide in the STEP program.
Journal: Postgraduate medicine
Published: January 24, 2023
Efficacy and safety of semaglutide for weight management: evidence from the STEP program.
Journal: Postgraduate medicine
Published: January 24, 2023
Efficacy and Safety of Liraglutide 3.0 mg in Individuals With Overweight or Obesity and Type 2 Diabetes Treated With Basal Insulin: The SCALE Insulin Randomized Controlled Trial.
Journal: Diabetes care
Published: August 30, 2019
Liraglutide 3.0 mg and Intensive Behavioral Therapy (IBT) for Obesity in Primary Care: The SCALE IBT Randomized Controlled Trial.
Journal: Obesity (Silver Spring, Md.)
Published: August 15, 2019
IDegLira improves patient-reported outcomes while using a simple regimen with fewer injections and dose adjustments compared with basal-bolus therapy.
Journal: Diabetes, obesity & metabolism
Published: May 10, 2019
Efficacy of iGlarLixi, a fixed-ratio combination of insulin glargine and lixisenatide, in patients with type 2 diabetes stratified as at high or low risk according to HEDIS measurements.
Journal: Diabetes, obesity & metabolism
Published: March 21, 2018
Semaglutide Added to Basal Insulin in Type 2 Diabetes (SUSTAIN 5): A Randomized, Controlled Trial.
Journal: The Journal of clinical endocrinology and metabolism
Published: January 09, 2018
Combination therapy with insulin glargine plus metformin but not insulin glargine plus sulfonylurea provides similar glycemic control to triple oral combination therapy in patients with type 2 diabetes uncontrolled with dual oral agent therapy.
Journal: Journal of diabetes and its complications
Published: February 25, 2015
The TRINITY Study: distribution of systolic blood pressure reductions.
Journal: Integrated blood pressure control
Published: August 01, 2013
Showing 1-12 of 12
Last Updated: 09/26/2026